Precision Biosciences (DTIL) Return on Capital Employed (2019 - 2026)
Precision Biosciences (DTIL) reported Return on Capital Employed of 27.66% for Q1 2026, up 970.0% year-over-year from 2.59% in Q1 2025, and up 38.98% on a QoQ basis from 45.33% in Q4 2025.
Precision Biosciences (DTIL) has 8 years of Return on Capital Employed data on file, last reported at 27.66% in Q1 2026.
- Quarterly Return on Capital Employed rose 970.0% year-over-year to 27.66% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27.66% (up 970.0% YoY) and the FY2025 annual result came in at 38.21%, down 1855.0% from the prior year.
- Return on Capital Employed improved to 27.66% in Q1 2026 per DTIL's latest filing, from 45.33% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 5.13% in Q2 2024 and bottomed at 103.8% in Q3 2025.
- The 5-year median for Return on Capital Employed is 37.36% (2025), against an average of 39.86%.
- The widest annual swing landed in 2022, when Return on Capital Employed jumped 4229 bps; it then plunged 9282 bps in 2025.
- Tracing DTIL's Return on Capital Employed over 5 years: stood at 42.85% in 2022, then gained by 9 bps to 39.02% in 2023, then soared by 48 bps to 20.15% in 2024, then slumped by 125 bps to 45.33% in 2025, then surged by 39 bps to 27.66% in 2026.
- Per Business Quant, the three latest DTIL Return on Capital Employed figures stand at 27.66% (Q1 2026), 45.33% (Q4 2025), and 103.8% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Precision Biosciences | 171.70 Mn | 70.52 Mn | - | -27.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.66% |
| Dec 31, 2025 | -45.33% |
| Sep 30, 2025 | -103.80% |
| Jun 30, 2025 | -87.40% |
| Mar 31, 2025 | -37.36% |
| Dec 31, 2024 | -20.15% |
| Sep 30, 2024 | -10.98% |
| Jun 30, 2024 | -5.13% |
| Mar 31, 2024 | -24.88% |
| Dec 31, 2023 | -39.02% |
| Sep 30, 2023 | -33.46% |
| Jun 30, 2023 | -31.65% |
| Mar 31, 2023 | -39.94% |
| Dec 31, 2022 | -42.85% |
| Sep 30, 2022 | -45.81% |
| Jun 30, 2022 | -53.50% |
| Mar 31, 2022 | -28.67% |
| Dec 31, 2021 | -21.47% |
| Sep 30, 2021 | -16.72% |
| Jun 30, 2021 | -22.21% |
| Mar 31, 2021 | -70.96% |
| Dec 31, 2020 | -94.20% |
| Sep 30, 2020 | -80.48% |
| Jun 30, 2020 | -63.16% |
| Mar 31, 2020 | -47.38% |
| Dec 31, 2019 | -39.49% |
| Sep 30, 2019 | -33.60% |
| Jun 30, 2019 | -34.35% |
| Mar 31, 2019 | -71.54% |